Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A1 | P04798 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | ASH1L | Q9NR48 | 1/20 | 0.31 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29365059 | 0.63 | CYP2B6 (0.43) | CYP1A1CYP1A2CYP2B6 | |
| SCHEMBL29372595 | 0.63 | CYP2B6 (0.43) | CYP1A1CYP1A2CYP2B6 | |
| SCHEMBL28185909 | 0.62 | MET (0.40) | CYP1A1CYP1A2CYP2B6 | |
| SCHEMBL29657636 | 0.62 | CYP1A1 (0.40) | CYP1A1CYP1A2CYP2B6 | |
| SCHEMBL8553982 | 0.62 | CYP1A1 (0.40) | CYP1A1CYP1A2CYP2B6 | |
| SCHEMBL11792905 | 0.60 | CYP1A1 (0.34) | CYP1A1CYP1A2CYP2B6 | |
| SCHEMBL29609923 | 0.60 | CYP1A1 (0.34) | CYP1A1CYP1A2CYP2B6 | |
| SCHEMBL30602816 | 0.60 | CYP1A1 (0.34) | CYP1A1CYP1A2CYP2B6 | |
| SCHEMBL3708936 | 0.59 | HPRT1 (0.47) | CYP1A1CYP1A2CYP2B6 | |
| SCHEMBL2458273 | 0.58 | MAPT (0.47) | CYP1A1CYP1A2CYP2B6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7528164-B2 | Substituted 4-aryl-4h-pyrrolo[2,3-h]chromenes and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. (US) | 2009-05-05 | — | — | US | disclosed |
| US-20060104998-A1 | Substituted 4-aryl-4h-pyrrolo[2,3-h]chromenes and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. (US) | 2006-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060104998-A1 | Substituted 4-aryl-4h-pyrrolo[2,3-h]chromenes and analogs as activators of caspases and inducers of apoptosis and the use thereof | CASP3, CASP4, CASP2 | CYP1A1 116/4885CYP1A2 244/4885ASH1L 3635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.